Welcome to Peptide Card of AntiTbPdb
| This page displays user query in tabular form. |
GLRRLFADQLVGRRNI-CO2CH3 details |
| Primary information | |
|---|---|
| ID | antitb_1201, |
| Name | 24684906 |
| N-Terminal modification | Lassomycin |
| C-Terminal Modification | GLRRLFADQLVGRRNI-CO2CH3 |
| Chemical Modification | Involved in Cyclic formation |
| Linear/Cyclic | Addition of Methyl ester |
| Length | Formation of an amide bond between N-terminal amine and the side chain carboxyl group of Asp8. |
| Chirality | Cyclic |
| Nature | 16 |
| Source | L |
| Origin | Highly Basic |
| Species | Natural |
| Strain | Extracts from soil actinomycetes |
| Inhibition Concentration | Mycobacterium tuberculosis |
| In Vitro/ In vivo | Mycobacterium tuberculosis H37Rv |
| Cell Line | MIC = 0.78–1.56 μg/ml or 0.41–0.83 μM |
| Inhibition Concentration | In vitro |
| Sequence | 2014 |
| Cytotoxicity | Human NIH 3T3 and HepG2, erythrocytes |
| In vivo Model | NA |
| Lethal Dose | Low cytotoxicty (IC50, 350 μg/ml) against human NIH 3T3 and HepG2 cells |
| Immune Responce | None |
| Mechanism of Action | NA |
| Target | NA |
| Combination Therapy | Uncoupling ATPase from proteolytic activity |
| Other activities | ClpC1 ATPase complex |
| PMID | None |
| Year of Publication | Antibacterial (other actinobacteria, gram positive and gram negative bacteria) |
| Tertiary Structure (Technique) | Not Predicted), |
| Primary information | |
|---|---|
| ID | antitb_1202, |
| Name | 24684906 |
| N-Terminal modification | Lassomycin |
| C-Terminal Modification | GLRRLFADQLVGRRNI-CO2CH3 |
| Chemical Modification | Involved in Cyclic formation |
| Linear/Cyclic | Addition of Methyl ester |
| Length | Formation of an amide bond between N-terminal amine and the side chain carboxyl group of Asp8. |
| Chirality | Cyclic |
| Nature | 16 |
| Source | L |
| Origin | Highly Basic |
| Species | Natural |
| Strain | Extracts from soil actinomycetes |
| Inhibition Concentration | Mycobacterium tuberculosis |
| In Vitro/ In vivo | Mycobacterium tuberculosis susceptible 186 clinical isolate |
| Cell Line | MIC = 1.56 μg/ml or 0.83 μM |
| Inhibition Concentration | In vitro |
| Sequence | 2014 |
| Cytotoxicity | Human NIH 3T3 and HepG2, erythrocytes |
| In vivo Model | NA |
| Lethal Dose | Low cytotoxicty (IC50, 350 μg/ml) against human NIH 3T3 and HepG2 cells |
| Immune Responce | None |
| Mechanism of Action | NA |
| Target | NA |
| Combination Therapy | Uncoupling ATPase from proteolytic activity |
| Other activities | ClpC1 ATPase complex |
| PMID | None |
| Year of Publication | Antibacterial (other actinobacteria, gram positive and gram negative bacteria) |
| Tertiary Structure (Technique) | Not Predicted), |
| Primary information | |
|---|---|
| ID | antitb_1203, |
| Name | 24684906 |
| N-Terminal modification | Lassomycin |
| C-Terminal Modification | GLRRLFADQLVGRRNI-CO2CH3 |
| Chemical Modification | Involved in Cyclic formation |
| Linear/Cyclic | Addition of Methyl ester |
| Length | Formation of an amide bond between N-terminal amine and the side chain carboxyl group of Asp8. |
| Chirality | Cyclic |
| Nature | 16 |
| Source | L |
| Origin | Highly Basic |
| Species | Natural |
| Strain | Extracts from soil actinomycetes |
| Inhibition Concentration | Mycobacterium tuberculosis |
| In Vitro/ In vivo | Mycobacterium tuberculosis susceptible 83 clinical isolate |
| Cell Line | MIC = 1.56-3.1 μg/ml or 0.83 μM |
| Inhibition Concentration | In vitro |
| Sequence | 2014 |
| Cytotoxicity | Human NIH 3T3 and HepG2, erythrocytes |
| In vivo Model | NA |
| Lethal Dose | Low cytotoxicty (IC50, 350 μg/ml) against human NIH 3T3 and HepG2 cells |
| Immune Responce | None |
| Mechanism of Action | NA |
| Target | NA |
| Combination Therapy | Uncoupling ATPase from proteolytic activity |
| Other activities | ClpC1 ATPase complex |
| PMID | None |
| Year of Publication | Antibacterial (other actinobacteria, gram positive and gram negative bacteria) |
| Tertiary Structure (Technique) | Not Predicted), |
| Primary information | |
|---|---|
| ID | antitb_1204, |
| Name | 24684906 |
| N-Terminal modification | Lassomycin |
| C-Terminal Modification | GLRRLFADQLVGRRNI-CO2CH3 |
| Chemical Modification | Involved in Cyclic formation |
| Linear/Cyclic | Addition of Methyl ester |
| Length | Formation of an amide bond between N-terminal amine and the side chain carboxyl group of Asp8. |
| Chirality | Cyclic |
| Nature | 16 |
| Source | L |
| Origin | Highly Basic |
| Species | Natural |
| Strain | Extracts from soil actinomycetes |
| Inhibition Concentration | Mycobacterium tuberculosis |
| In Vitro/ In vivo | Mycobacterium tuberculosis resistant to INH, STR (84) |
| Cell Line | MIC = 1.56-3.1 μg/ml or 0.83 μM |
| Inhibition Concentration | In vitro |
| Sequence | 2014 |
| Cytotoxicity | Human NIH 3T3 and HepG2, erythrocytes |
| In vivo Model | NA |
| Lethal Dose | Low cytotoxicty (IC50, 350 μg/ml) against human NIH 3T3 and HepG2 cells |
| Immune Responce | None |
| Mechanism of Action | NA |
| Target | NA |
| Combination Therapy | Uncoupling ATPase from proteolytic activity |
| Other activities | ClpC1 ATPase complex |
| PMID | None |
| Year of Publication | Antibacterial (other actinobacteria, gram positive and gram negative bacteria) |
| Tertiary Structure (Technique) | Not Predicted), |
| Primary information | |
|---|---|
| ID | antitb_1205, |
| Name | 24684906 |
| N-Terminal modification | Lassomycin |
| C-Terminal Modification | GLRRLFADQLVGRRNI-CO2CH3 |
| Chemical Modification | Involved in Cyclic formation |
| Linear/Cyclic | Addition of Methyl ester |
| Length | Formation of an amide bond between N-terminal amine and the side chain carboxyl group of Asp8. |
| Chirality | Cyclic |
| Nature | 16 |
| Source | L |
| Origin | Highly Basic |
| Species | Natural |
| Strain | Extracts from soil actinomycetes |
| Inhibition Concentration | Mycobacterium tuberculosis |
| In Vitro/ In vivo | Mycobacterium tuberculosis resistant to INH, RIF (85) |
| Cell Line | MIC = 1.56-3.1 μg/ml or 0.83 μM |
| Inhibition Concentration | In vitro |
| Sequence | 2014 |
| Cytotoxicity | Human NIH 3T3 and HepG2, erythrocytes |
| In vivo Model | NA |
| Lethal Dose | Low cytotoxicty (IC50, 350 μg/ml) against human NIH 3T3 and HepG2 cells |
| Immune Responce | None |
| Mechanism of Action | NA |
| Target | NA |
| Combination Therapy | Uncoupling ATPase from proteolytic activity |
| Other activities | ClpC1 ATPase complex |
| PMID | None |
| Year of Publication | Antibacterial (other actinobacteria, gram positive and gram negative bacteria) |
| Tertiary Structure (Technique) | Not Predicted), |
| Primary information | |
|---|---|
| ID | antitb_1206, |
| Name | 24684906 |
| N-Terminal modification | Lassomycin |
| C-Terminal Modification | GLRRLFADQLVGRRNI-CO2CH3 |
| Chemical Modification | Involved in Cyclic formation |
| Linear/Cyclic | Addition of Methyl ester |
| Length | Formation of an amide bond between N-terminal amine and the side chain carboxyl group of Asp8. |
| Chirality | Cyclic |
| Nature | 16 |
| Source | L |
| Origin | Highly Basic |
| Species | Natural |
| Strain | Extracts from soil actinomycetes |
| Inhibition Concentration | Mycobacterium tuberculosis |
| In Vitro/ In vivo | Mycobacterium tuberculosis resistant to INH, RIF (7) |
| Cell Line | MIC = 1.56 μg/ml or 0.83 μM |
| Inhibition Concentration | In vitro |
| Sequence | 2014 |
| Cytotoxicity | Human NIH 3T3 and HepG2, erythrocytes |
| In vivo Model | NA |
| Lethal Dose | Low cytotoxicty (IC50, 350 μg/ml) against human NIH 3T3 and HepG2 cells |
| Immune Responce | None |
| Mechanism of Action | NA |
| Target | NA |
| Combination Therapy | Uncoupling ATPase from proteolytic activity |
| Other activities | ClpC1 ATPase complex |
| PMID | None |
| Year of Publication | Antibacterial (other actinobacteria, gram positive and gram negative bacteria) |
| Tertiary Structure (Technique) | Not Predicted), |
| Primary information | |
|---|---|
| ID | antitb_1207, |
| Name | 24684906 |
| N-Terminal modification | Lassomycin |
| C-Terminal Modification | GLRRLFADQLVGRRNI-CO2CH3 |
| Chemical Modification | Involved in Cyclic formation |
| Linear/Cyclic | Addition of Methyl ester |
| Length | Formation of an amide bond between N-terminal amine and the side chain carboxyl group of Asp8. |
| Chirality | Cyclic |
| Nature | 16 |
| Source | L |
| Origin | Highly Basic |
| Species | Natural |
| Strain | Extracts from soil actinomycetes |
| Inhibition Concentration | Mycobacterium tuberculosis |
| In Vitro/ In vivo | Mycobacterium tuberculosis resistant to INH, RIF, STR (86) |
| Cell Line | MIC = 1.56 μg/ml or 0.83 μM |
| Inhibition Concentration | In vitro |
| Sequence | 2014 |
| Cytotoxicity | Human NIH 3T3 and HepG2, erythrocytes |
| In vivo Model | NA |
| Lethal Dose | Low cytotoxicty (IC50, 350 μg/ml) against human NIH 3T3 and HepG2 cells |
| Immune Responce | None |
| Mechanism of Action | NA |
| Target | NA |
| Combination Therapy | Uncoupling ATPase from proteolytic activity |
| Other activities | ClpC1 ATPase complex |
| PMID | None |
| Year of Publication | Antibacterial (other actinobacteria, gram positive and gram negative bacteria) |
| Tertiary Structure (Technique) | Not Predicted), |
| Primary information | |
|---|---|
| ID | antitb_1208, |
| Name | 24684906 |
| N-Terminal modification | Lassomycin |
| C-Terminal Modification | GLRRLFADQLVGRRNI-CO2CH3 |
| Chemical Modification | Involved in Cyclic formation |
| Linear/Cyclic | Addition of Methyl ester |
| Length | Formation of an amide bond between N-terminal amine and the side chain carboxyl group of Asp8. |
| Chirality | Cyclic |
| Nature | 16 |
| Source | L |
| Origin | Highly Basic |
| Species | Natural |
| Strain | Extracts from soil actinomycetes |
| Inhibition Concentration | Mycobacterium tuberculosis |
| In Vitro/ In vivo | Mycobacterium tuberculosis resistant to INH, RIF, STR, FQ (136) |
| Cell Line | MIC = 0.78 μg/ml or 0.41 μM |
| Inhibition Concentration | In vitro |
| Sequence | 2014 |
| Cytotoxicity | Human NIH 3T3 and HepG2, erythrocytes |
| In vivo Model | NA |
| Lethal Dose | Low cytotoxicty (IC50, 350 μg/ml) against human NIH 3T3 and HepG2 cells |
| Immune Responce | None |
| Mechanism of Action | NA |
| Target | NA |
| Combination Therapy | Uncoupling ATPase from proteolytic activity |
| Other activities | ClpC1 ATPase complex |
| PMID | None |
| Year of Publication | Antibacterial (other actinobacteria, gram positive and gram negative bacteria) |
| Tertiary Structure (Technique) | Not Predicted), |
| Primary information | |
|---|---|
| ID | antitb_1209, |
| Name | 24684906 |
| N-Terminal modification | Lassomycin |
| C-Terminal Modification | GLRRLFADQLVGRRNI-CO2CH3 |
| Chemical Modification | Involved in Cyclic formation |
| Linear/Cyclic | Addition of Methyl ester |
| Length | Formation of an amide bond between N-terminal amine and the side chain carboxyl group of Asp8. |
| Chirality | Cyclic |
| Nature | 16 |
| Source | L |
| Origin | Highly Basic |
| Species | Natural |
| Strain | Extracts from soil actinomycetes |
| Inhibition Concentration | Mycobacterium tuberculosis |
| In Vitro/ In vivo | Mycobacterium tuberculosis resistant to INH, RIF, STR, FQ (133) |
| Cell Line | MIC = 0.78 μg/ml or 0.41 μM |
| Inhibition Concentration | In vitro |
| Sequence | 2014 |
| Cytotoxicity | Human NIH 3T3 and HepG2, erythrocytes |
| In vivo Model | NA |
| Lethal Dose | Low cytotoxicty (IC50, 350 μg/ml) against human NIH 3T3 and HepG2 cells |
| Immune Responce | None |
| Mechanism of Action | NA |
| Target | NA |
| Combination Therapy | Uncoupling ATPase from proteolytic activity |
| Other activities | ClpC1 ATPase complex |
| PMID | None |
| Year of Publication | Antibacterial (other actinobacteria, gram positive and gram negative bacteria) |
| Tertiary Structure (Technique) | Not Predicted), |
| Primary information | |
|---|---|
| ID | antitb_1210, |
| Name | 24684906 |
| N-Terminal modification | Lassomycin |
| C-Terminal Modification | GLRRLFADQLVGRRNI-CO2CH3 |
| Chemical Modification | Involved in Cyclic formation |
| Linear/Cyclic | Addition of Methyl ester |
| Length | Formation of an amide bond between N-terminal amine and the side chain carboxyl group of Asp8. |
| Chirality | Cyclic |
| Nature | 16 |
| Source | L |
| Origin | Highly Basic |
| Species | Natural |
| Strain | Extracts from soil actinomycetes |
| Inhibition Concentration | Mycobacterium tuberculosis |
| In Vitro/ In vivo | Mycobacterium tuberculosis resistant to INH, RIF, STR, FQ (189) |
| Cell Line | MIC = 3.1 μg/ml or 1.65 μM |
| Inhibition Concentration | In vitro |
| Sequence | 2014 |
| Cytotoxicity | Human NIH 3T3 and HepG2, erythrocytes |
| In vivo Model | NA |
| Lethal Dose | Low cytotoxicty (IC50, 350 μg/ml) against human NIH 3T3 and HepG2 cells |
| Immune Responce | None |
| Mechanism of Action | NA |
| Target | NA |
| Combination Therapy | Uncoupling ATPase from proteolytic activity |
| Other activities | ClpC1 ATPase complex |
| PMID | None |
| Year of Publication | Antibacterial (other actinobacteria, gram positive and gram negative bacteria) |
| Tertiary Structure (Technique) | Not Predicted), |
| Primary information | |
|---|---|
| ID | antitb_1211, |
| Name | 24684906 |
| N-Terminal modification | Lassomycin |
| C-Terminal Modification | GLRRLFADQLVGRRNI-CO2CH3 |
| Chemical Modification | Involved in Cyclic formation |
| Linear/Cyclic | Addition of Methyl ester |
| Length | Formation of an amide bond between N-terminal amine and the side chain carboxyl group of Asp8. |
| Chirality | Cyclic |
| Nature | 16 |
| Source | L |
| Origin | Highly Basic |
| Species | Natural |
| Strain | Extracts from soil actinomycetes |
| Inhibition Concentration | Mycobacterium tuberculosis |
| In Vitro/ In vivo | Mycobacterium tuberculosis resistant to INH, RIF, EMB, FQ (3) |
| Cell Line | MIC = 3.1 μg/ml or 1.65 μM |
| Inhibition Concentration | In vitro |
| Sequence | 2014 |
| Cytotoxicity | Human NIH 3T3 and HepG2, erythrocytes |
| In vivo Model | NA |
| Lethal Dose | Low cytotoxicty (IC50, 350 μg/ml) against human NIH 3T3 and HepG2 cells |
| Immune Responce | None |
| Mechanism of Action | NA |
| Target | NA |
| Combination Therapy | Uncoupling ATPase from proteolytic activity |
| Other activities | ClpC1 ATPase complex |
| PMID | None |
| Year of Publication | Antibacterial (other actinobacteria, gram positive and gram negative bacteria) |
| Tertiary Structure (Technique) | Not Predicted), |
| Primary information | |
|---|---|
| ID | antitb_1212, |
| Name | 24684906 |
| N-Terminal modification | Lassomycin |
| C-Terminal Modification | GLRRLFADQLVGRRNI-CO2CH3 |
| Chemical Modification | Involved in Cyclic formation |
| Linear/Cyclic | Addition of Methyl ester |
| Length | Formation of an amide bond between N-terminal amine and the side chain carboxyl group of Asp8. |
| Chirality | Cyclic |
| Nature | 16 |
| Source | L |
| Origin | Highly Basic |
| Species | Natural |
| Strain | Extracts from soil actinomycetes |
| Inhibition Concentration | Mycobacterium tuberculosis |
| In Vitro/ In vivo | Mycobacterium tuberculosis resistant to INH, RIF, EMB, PZA, FQ (30) |
| Cell Line | MIC = 0.78 μg/ml or 0.41 μM |
| Inhibition Concentration | In vitro |
| Sequence | 2014 |
| Cytotoxicity | Human NIH 3T3 and HepG2, erythrocytes |
| In vivo Model | NA |
| Lethal Dose | Low cytotoxicty (IC50, 350 μg/ml) against human NIH 3T3 and HepG2 cells |
| Immune Responce | None |
| Mechanism of Action | NA |
| Target | NA |
| Combination Therapy | Uncoupling ATPase from proteolytic activity |
| Other activities | ClpC1 ATPase complex |
| PMID | None |
| Year of Publication | Antibacterial (other actinobacteria, gram positive and gram negative bacteria) |
| Tertiary Structure (Technique) | Not Predicted), |
| Primary information | |
|---|---|
| ID | antitb_1213, |
| Name | 24684906 |
| N-Terminal modification | Lassomycin |
| C-Terminal Modification | GLRRLFADQLVGRRNI-CO2CH3 |
| Chemical Modification | Involved in Cyclic formation |
| Linear/Cyclic | Addition of Methyl ester |
| Length | Formation of an amide bond between N-terminal amine and the side chain carboxyl group of Asp8. |
| Chirality | Cyclic |
| Nature | 16 |
| Source | L |
| Origin | Highly Basic |
| Species | Natural |
| Strain | Extracts from soil actinomycetes |
| Inhibition Concentration | Mycobacterium tuberculosis |
| In Vitro/ In vivo | Mycobacterium tuberculosis resistant to INH, RIF, EMB, PZA, FQ (181) |
| Cell Line | MIC = 0.78 μg/ml or 0.41 μM |
| Inhibition Concentration | In vitro |
| Sequence | 2014 |
| Cytotoxicity | Human NIH 3T3 and HepG2, erythrocytes |
| In vivo Model | NA |
| Lethal Dose | Low cytotoxicty (IC50, 350 μg/ml) against human NIH 3T3 and HepG2 cells |
| Immune Responce | None |
| Mechanism of Action | NA |
| Target | NA |
| Combination Therapy | Uncoupling ATPase from proteolytic activity |
| Other activities | ClpC1 ATPase complex |
| PMID | None |
| Year of Publication | Antibacterial (other actinobacteria, gram positive and gram negative bacteria) |
| Tertiary Structure (Technique) | Not Predicted), |
| Primary information | |
|---|---|
| ID | antitb_1214, |
| Name | 24684906 |
| N-Terminal modification | Lassomycin |
| C-Terminal Modification | GLRRLFADQLVGRRNI-CO2CH3 |
| Chemical Modification | Involved in Cyclic formation |
| Linear/Cyclic | Addition of Methyl ester |
| Length | Formation of an amide bond between N-terminal amine and the side chain carboxyl group of Asp8. |
| Chirality | Cyclic |
| Nature | 16 |
| Source | L |
| Origin | Highly Basic |
| Species | Natural |
| Strain | Extracts from soil actinomycetes |
| Inhibition Concentration | Mycobacterium tuberculosis |
| In Vitro/ In vivo | Mycobacterium tuberculosis resistant to INH, RIF, STR, EMB, PZA, FQ (183) |
| Cell Line | MIC = 3.1 μg/ml or 1.65 μM |
| Inhibition Concentration | In vitro |
| Sequence | 2014 |
| Cytotoxicity | Human NIH 3T3 and HepG2, erythrocytes |
| In vivo Model | NA |
| Lethal Dose | Low cytotoxicty (IC50, 350 μg/ml) against human NIH 3T3 and HepG2 cells |
| Immune Responce | None |
| Mechanism of Action | NA |
| Target | NA |
| Combination Therapy | Uncoupling ATPase from proteolytic activity |
| Other activities | ClpC1 ATPase complex |
| PMID | None |
| Year of Publication | Antibacterial (other actinobacteria, gram positive and gram negative bacteria) |
| Tertiary Structure (Technique) | Not Predicted), |
| Primary information | |
|---|---|
| ID | antitb_1215, |
| Name | 24684906 |
| N-Terminal modification | Lassomycin |
| C-Terminal Modification | GLRRLFADQLVGRRNI-CO2CH3 |
| Chemical Modification | Involved in Cyclic formation |
| Linear/Cyclic | Addition of Methyl ester |
| Length | Formation of an amide bond between N-terminal amine and the side chain carboxyl group of Asp8. |
| Chirality | Cyclic |
| Nature | 16 |
| Source | L |
| Origin | Highly Basic |
| Species | Natural |
| Strain | Extracts from soil actinomycetes |
| Inhibition Concentration | Mycobacterium tuberculosis |
| In Vitro/ In vivo | Mycobacterium tuberculosis resistant to INH, RIF, STR, EMB, PZA, FQ (188) |
| Cell Line | MIC = 3.1 μg/ml or 1.65 μM |
| Inhibition Concentration | In vitro |
| Sequence | 2014 |
| Cytotoxicity | Human NIH 3T3 and HepG2, erythrocytes |
| In vivo Model | NA |
| Lethal Dose | Low cytotoxicty (IC50, 350 μg/ml) against human NIH 3T3 and HepG2 cells |
| Immune Responce | None |
| Mechanism of Action | NA |
| Target | NA |
| Combination Therapy | Uncoupling ATPase from proteolytic activity |
| Other activities | ClpC1 ATPase complex |
| PMID | None |
| Year of Publication | Antibacterial (other actinobacteria, gram positive and gram negative bacteria) |
| Tertiary Structure (Technique) | Not Predicted), |
| Primary information | |
|---|---|
| ID | antitb_1216, |
| Name | 24684906 |
| N-Terminal modification | Lassomycin |
| C-Terminal Modification | GLRRLFADQLVGRRNI-CO2CH3 |
| Chemical Modification | Involved in Cyclic formation |
| Linear/Cyclic | Addition of Methyl ester |
| Length | Formation of an amide bond between N-terminal amine and the side chain carboxyl group of Asp8. |
| Chirality | Cyclic |
| Nature | 16 |
| Source | L |
| Origin | Highly Basic |
| Species | Natural |
| Strain | Extracts from soil actinomycetes |
| Inhibition Concentration | Mycobacterium tuberculosis |
| In Vitro/ In vivo | Mycobacterium tuberculosis mc26020 |
| Cell Line | MIC = 0.39-0.78 μg/ml or 0.21-0.41 μM |
| Inhibition Concentration | In vitro |
| Sequence | 2014 |
| Cytotoxicity | Human NIH 3T3 and HepG2, erythrocytes |
| In vivo Model | NA |
| Lethal Dose | Low cytotoxicty (IC50, 350 μg/ml) against human NIH 3T3 and HepG2 cells |
| Immune Responce | None |
| Mechanism of Action | NA |
| Target | NA |
| Combination Therapy | Uncoupling ATPase from proteolytic activity |
| Other activities | ClpC1 ATPase complex |
| PMID | None |
| Year of Publication | Antibacterial (other actinobacteria, gram positive and gram negative bacteria) |
| Tertiary Structure (Technique) | Not Predicted), |
| Primary information | |
|---|---|
| ID | antitb_1217, |
| Name | 24684906 |
| N-Terminal modification | Lassomycin |
| C-Terminal Modification | GLRRLFADQLVGRRNI-CO2CH3 |
| Chemical Modification | Involved in Cyclic formation |
| Linear/Cyclic | Addition of Methyl ester |
| Length | Formation of an amide bond between N-terminal amine and the side chain carboxyl group of Asp8. |
| Chirality | Cyclic |
| Nature | 16 |
| Source | L |
| Origin | Highly Basic |
| Species | Natural |
| Strain | Extracts from soil actinomycetes |
| Inhibition Concentration | Mycobacterium avium |
| In Vitro/ In vivo | Mycobacterium avium subsp. Paratuberculosis |
| Cell Line | MIC = 0.125-0.25 μg/ml or 0.07-0.13 μM |
| Inhibition Concentration | In vitro |
| Sequence | 2014 |
| Cytotoxicity | Human NIH 3T3 and HepG2, erythrocytes |
| In vivo Model | NA |
| Lethal Dose | Low cytotoxicty (IC50, 350 μg/ml) against human NIH 3T3 and HepG2 cells |
| Immune Responce | None |
| Mechanism of Action | NA |
| Target | NA |
| Combination Therapy | Uncoupling ATPase from proteolytic activity |
| Other activities | ClpC1 ATPase complex |
| PMID | None |
| Year of Publication | Antibacterial (other actinobacteria, gram positive and gram negative bacteria) |
| Tertiary Structure (Technique) | Not Predicted), |
| Primary information | |
|---|---|
| ID | antitb_1218, |
| Name | 24684906 |
| N-Terminal modification | Lassomycin |
| C-Terminal Modification | GLRRLFADQLVGRRNI-CO2CH3 |
| Chemical Modification | Involved in Cyclic formation |
| Linear/Cyclic | Addition of Methyl ester |
| Length | Formation of an amide bond between N-terminal amine and the side chain carboxyl group of Asp8. |
| Chirality | Cyclic |
| Nature | 16 |
| Source | L |
| Origin | Highly Basic |
| Species | Natural |
| Strain | Extracts from soil actinomycetes |
| Inhibition Concentration | Mycobacterium smegmatis |
| In Vitro/ In vivo | Mycobacterium smegmatis |
| Cell Line | MIC = 0.78-2 μg/ml or 0.41-1.06 μM |
| Inhibition Concentration | In vitro |
| Sequence | 2014 |
| Cytotoxicity | Human NIH 3T3 and HepG2, erythrocytes |
| In vivo Model | NA |
| Lethal Dose | Low cytotoxicty (IC50, 350 μg/ml) against human NIH 3T3 and HepG2 cells |
| Immune Responce | None |
| Mechanism of Action | NA |
| Target | NA |
| Combination Therapy | Uncoupling ATPase from proteolytic activity |
| Other activities | ClpC1 ATPase complex |
| PMID | None |
| Year of Publication | Antibacterial (other actinobacteria, gram positive and gram negative bacteria) |
| Tertiary Structure (Technique) | Not Predicted), |